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Innate immunity is the first line of host defense against infection by microbial 
pathogens, including viruses, bacteria and parasites. Recognition of nucleic 
acids by innate immune sensors is an important means to detect and protect 
against of pathogens in infected cells. In this project, we show that the 
cytosolic DNA sensor STING may regulate the levels of cytosolic DNA in 
cancer cells. Activation of STING in infected cells leads to the production of 
type I interferons. In accordance, constitutive expression of type I interferons 
partially depended on STING in cancer cells. In summary, our data suggest 












List of illustrations 
 
Figure 1.1 Overview of DNA damage responses 
Figure 1.2 Overview of the IFN receptor signaling pathways 
Figure 1.3 Overview of cGAS-STING pathways 


















List of Figures 
 
Figure 3.1 Generation of STING deficient cells by CRISPR 
Figure 3.2 STING deficiency decreases the levels of cytosolic DNA in cancer 
cells 
Figure 3.3 Ara-C does not increase the levels of cytosolic DNA in 
STING-deficient cells 
Figure 4.1 Loss of STING represses the expression of type I IFNs in cancer 
cells 
Figure 4.2 Aphidicolin does not induce type I IFNs expression in 
STING-deficient cancer cells 
Figure 4.3 Type I IFNs expression does not respond to dsDNA stimulation in 
STING-deficient cells 
Figure 5.1 dsDNA transfection can induce type I IFNs production in HeLa 
cells but not 293T cells 
Figure 5.2 CDNs but not dsDNA can induce type I IFNs expression in 293T 
cells 










List of Abbreviations 
 
A 
AIM2: absent in melanoma 2 
Ara-C: Arabinosylcytosine 
ATM: ataxia telangiectasia, mutated 
ATR: ATM- and Rad3-related 
 
B 
BASC: BRCA1-associated genome surveillance complex 
BRCA1: breast cancer type 1 susceptibility protein 
 
C 
CDN: cyclic dinucleotide 
cGAMP : cyclic GMP-AMP 
cGAS: cyclic guanosine monophosphate-adenosine monophosphate synthase 
CHK: checkpoint kinase 
CRISPR: Clustered regularly interspaced short palindromic repeats 
 
D 
DAMP: damage-associated molecular pattern 
DAPI: 4',6-diamidino-2-phenylindole 
DDR: DNA damage response 
DDX41: DEAD(Asp-Glu-Ala-Asp) box polypeptide 41 
DMSO: dimethyl sulfoxide 
DNA: deoxyribonucleic acid 
DNA-PK: DNA protein kinase 
DNase: deoxyribonuclease 
DSB: double strand break 
x 
dsDNA: double-stranded DNA 
 
E 
ER: endoplasmic reticulum 
 
F 
FBS: fetal bovine serum 
FGF2: fibroblast growth factor 2 
 
G 
GAPDH: glyceraldehyde 3-phosphate dehydrogenase 
GFP: green fluorescent protein 
 
H 
HDAC: histone deacetylases 
HEPES: 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid 
HPRT: Hypoxanthine-guanine phosphoribosyltransferase 
HSV1: herpes simplex virus 1 
 
I 
IFI16: interferon gamma inducible protein 16 
IFN: interferon 
IRF3: IFN-regulator factor 3 
ISGF3: IFN-stimulated gene factor 3 
ISRE: IFN-stimulated response elements 
 
J 
JAK1: Janus kinase 1 




MDR: multidrug resistance 
MNDA: myeloid cell nuclear differentiation antigen 
MRP: MITA-related protein 
 
N 
NF-κB: nuclear factor-κB 
NHEJ: non-homologous end joining 
HDR: homology-directed repair 
NK: Nature killer 
NLR: NOD-like receptor 
NOD: nucleotide-binding and oligomerization domain 
 
P 
PAMP: pathogen-associated molecular pattern 
PI3K: phosphoinositide 3-kinase 
PIKK: PI3K-related protein kinase 
PRR: pattern recognition receptor 
 
R 
RGS5: regulator of G-protein signaling 5 
RIG-I: retinoid acid-inducible gene-I 
RIPA: Radio-Immunoprecipitation Assay 
RLR: RIG-like receptor 




SAPK: stress-activated protein kinase 
SDS-PAGE: sodium dodecyl sulfate polyacrylamide gel electrophoresis 
xii 
ssDNA: single-stranded DNA 
STAT: signal transducer and activator of transcription 
STING: stimulator of interferon gene 
 
T 
TBK1: TANK-binding kinase 1  
TLR: Toll-like receptor 
TYK2: tyrosine kinase 2 
 
V 
VEGF: vascular endothelial growth factor 
 
Z 

























In addition to the cell intrinsic barriers to tumorigenesis and tumor formation 
mediated by tumor suppressors such as p53, the immune system has also been 
involved in tumor surveillance in several aspects (Lesokhin et al., 2015). The 
innate immune response consists of a series of cellular sensors and signaling 
pathways that activates defense mechanisms in response to microbe invasion 
(Czarny et al., 2015). The innate immune system responds to the presence of 
pathogens or danger by recognition of pathogen-associated molecular patterns 
(PAMPs) or damage-associated molecular pattern (DAMPs) respectively, 
leading to altered gene expression, immune effector mechanisms and 
ultimately a return to homeostasis. PAMPs and DAMPs are detected by 
several classes of host pattern recognition receptors (PRRs) including the 
Toll-like receptors (TLRs), RIG-like receptors (RLRs), NOD-like receptors 
(NLRs) and C-type lectin receptors. These innate immunity responses finally 
result in the production of type I interferon (IFN) (Shimizu et al., 2014). 
1.1 DNA Damage Response (DDR) 
1.1.1 Overview of the DNA damage 
Accumulation of DNA damage has been involved in the phenotypic 
manifestations of aging in rodents and humans (Lombard et al., 2005). DNA 
damage can be induced by variety of activities such as endogenous or 
exogenous stresses, including oxidative stress, telomere erosion, oncogenic 
mutations, genotoxic stress and metabolic stress (Lo p´ez-Otı´n et al., 2013). 
The presence of DNA damage can cause cell-cycle arrest, apoptosis and cell 
3 
senescence. Accumulation of senescent cells can impair tissue regeneration 
and homeostasis which leads to metabolic dysfunction. In addition, it is 
reported that chronic inflammation associated with senescence has a crucial 
role in the processing of age-related diseases such as diabetes and cancer. 
1.1.2 Overview of the DNA damage response 
To defend alterations to the nuclear DNA, all organisms have developed a 
complex and efficient system for repairing DNA damage and eliminating cells 
that cannot be repaired, called DNA damage response (DDR) (Ciccia and 
Elledge, 2010). DDR is a signal-transduction pathway that directs and 
regulates cell-cycle transitions, DNA replications, DNA repair and apoptosis. 
The major regulators of DDR are the phosphoinositide 3-kinase (PI3K)- 
related protein kinases (PIKKs), including ataxia-telangiectasia mutated (ATM) 
and ATM and RAD3-related (ATR). ATM and ATR have similar biochemical 
and functional characteristics (Piotr Czarny, 2015). Both of them are large 
kinases with important sequence homology and tendency to phosphorylate Ser 
or Thr residues which are followed by Gln (Weber, 2014). Moreover, both 
phosphorylate a common set of substrates that leads to cell-cycle arrest and 
DNA repair. The ATM and ATR kinase are activated by different genomic 
insults. ATM seems to be activated primarily by double strand breaks (DSBs), 
while ATR is mainly involved in the response to stalled replication forks, 
although it can participate in the DDR to DSBs.  
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Upon DNA damage, ATM and ATR phosphorylate a multitude of 
substrates to induce the required cellular response (Ciccia and Elledge, 2010). 
Two classes of proteins are cooperated with them to transduce the DNA 
damage signal: transducer kinases and checkpoint mediators. Checkpoint 
mediators, such as MDC1, 53BP1 and BRCA1 for ATM (Shiloh and Ziv, 2013) 
and TopBP1 and claspin for ATR (Liu, 2006), can contribute to the activation 
of ATM and ATR by binding to the lesions and facilitating recruitment of DDR 
factor to the damage sites indirectly (Canman, 2003; Marechal, 2013). 
Transducer kinases are involved in spreading of the DNA damage signal 
through a phosphorylation way. Checkpoint kinase 1(CHK1) for ATR and 
CHK2 for ATM is known as the most important transducer kinases 
(Bekker-Jensen and Mailand, 2010).  
ATM creates a homodimer in its inactive form, which is recruited to the site of 
DSB by the Mre11-Rad50-Nbs1 (MRN) complex, further undergoes 
auto-phosphorylation and separates into two active monomers (Bakkenist, 
2003). After recruitment and activation, ATM and ATR interact with many 
mediators and performing proteins, including CHK1 and CHK2 involved in 
the cell cycle control, p53, which is a multifunctional protein, is crucial for 
cell survival and a famous tumor suppressor, breast cancer type 1 
susceptibility protein (BRCA1)-associated genome surveillance complex 
(BASC) involving DNA damage repair proteins (Wang, 2000; Kim,1999), 
histone deacetylases 1 and 2 (HDAC1 and HDAC2) responsible for 
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remodeling chromatin structure, and transcription factor FOXO3, regulating 
genes involved in DNA repair (Schmidt et al.,1999;Tran et al., 2002; 
Thurn,2013).  
 
Figure 1.1 Overview of DNA damage responses  
DNA damage can be induced by both exogenous chemical and physical factors, and 
by endogenous influences following from cellular and DNA metabolism. The DNA 
damage induction triggers the DNA damage response (DDR). Three proteins from the 
phosphatidylinositol 3-kinase-like protein kinases (PIKKs) family plays a major role 
in DDR: ataxia telangiectasia mutated (ATM), DNA protein kinase (DNA-PK) and 
ataxia telangiectasia and Rad3 related (ATR), two proteins of the poly (ADP-ribose) 
polymerase (PARP) family: PARP1 and PARP2, and heterotrimeric complex of Rad9, 
Rad1 and Hus1 (9–1–1 complex). These proteins are activated by either DNA damage 
itself or by other proteins. After ATM, ATR, DNA-PK, PARP1/2 or 9–1–1 complexes 
are activated, they transfer signals via signal mediators to regulate many cellular 
processes, including DNA repair, cell checkpoint activation or deactivation, activation 
or silencing of transcription, apoptosis and autophagy. Image taken from Piotr Czarny 




1.1.3 The role of the DNA damage response in tumorigenesis 
Genomic instability especially DNA damage is one of the hallmarks of cancer 
(Stratton et al., 2009). Although the specific DDR flaws remain unclear in 
most cancers, there is an incontrovertible connection between a particular 
DDR defect and the neoplastic phenotype in several cases. For instance, 
around 15% of sporadic colorectal tumors show abnormal changing in length 
of dinucleotide repeat sequences, which is a characteristic of microsatellite 
instability, which possibly be caused by defective mismatch repair that results 
in an inability to repair DNA replication errors. Microsatellite instability is 
also found in the familial form of the disease such as hereditary non-polyposis 
colorectal cancer (HNPCC), which is associated with loss of function mutated 
mismatch repair genes, such as MSH2 and MLH1 (Renwick et al., 2006). 
ATM mutations increase the susceptibility of carriers to cancer and were found 
in 0.5-1.0% of the population approximately (Swift et al., 1987). Mutations in 
ATR are unusual and probably only result in viability when they are 
heterozygous. 
Moreover, DDR has been reported to provide an important barrier to 
tumorigenesis (Bartek et al., 2001, Bartkova et al., 2005; Gorgoulis et al., 
2005). Uncontrolled cell proliferation, which is induced by oncogene 
activation or inactivation of certain tumor suppressors, leads to 
DNA-replication stress and continuous DNA-damage. All these events will 
lead to activation of the ATM/ATR-mediated signaling. The DDR is also 
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activated in early neoplastic lesions and exerts as a barrier against malignant 
tumor (Bartkova et al., 2005; Gorgoulis et al., 2005). Inactivation of DDR, 
which is arising through mutational or epigenetic inactivation of components 
in DDR, is further selected for during tumor development, which could 
facilitate tumorigenesis (Halazonetis et al., 2008). The DDR model explains 
the high frequency of DDR dysfunction or defects in different human cancers. 
 
1.2 Type I Interferons 
1.2.1 Overview of interferons (IFNs) 
Interferons (IFNs) are important immune-modulatory cytokines that are 
induced in response to a variety of viral and bacterial infections and help 
establish anti-microbial innate immunity (Peskta et al., 2004). According to 
their structure and utilization of specific receptors, IFNs are classified into 3 
distinct types: type I IFNs, type II IFNs, and type III IFNs. Type I IFNs consist 
of 14 subtypes of IFNα, a single IFNβ, IFNκ, IFNω, IFNε, IFNδ and IFNτ. All 
type I IFN members share a common heterodimetric IFNα/β receptor that is 
composed of IFNAR1 and IFNAR2 (Pestka et al., 2004; Hertzog & Willianms, 
2013). Type II IFNs are presented by a single member IFNγ, which interacts 
with a single IFNγ receptor with two chains, IFNGR1 and IFNGR2. Type III 
IFN is comprised of 3 members, IFN- λ1, IFN-λ2, and IFN-λ3 (also called 
IL-28A, IL-28B, and IL-29 respectively) that are closely related to the IL-10 
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family cytokines. Type I IFNs and the IFNα/β receptor, as well as the IFNγ 
receptor, are widely expressed in contrast to the restricted expression patterns 
of IFNγ, type III IFNs and the IFNγ receptor. IFNγ is mainly produced by T 
cells and NK cells and type III IFNs by leukocytes and epithelial cells (Pestka 
et al., 2004; Young et al., 2007; Kotenko et al., 2011). Type III IFNs are 
suggested to protect epithelial tissue from viral and bacterial infection because 
of its primary expression by epithelial cells. 
1.2.2 Type I IFN signaling pathway 
The most well defined type I IFNs are IFNα and IFNβ (Hertzog & Willianms, 
2013). Most types of cells produce IFNβ, while haematopoietic cells, 
especially plasmacytoid dendritic cells, are the predominant producers of 
IFNα. IFNβ is encoded IFNB gene, while 14 distinct genes encode IFNα 
various isoforms. Type I IFNs production is induced after the sensing of 
microbial products by pattern-recognition receptors (PRRs) (Paludan and 
Bowie, 2013; Goubau et al., 2013; Iwasaki, 2012) and by various cytokines.  
In the canonical type I IFN-induced signaling pathway, IFNAR engagement 
was reported to activate the receptor-associated protein tyrosine kinase 
2(TYK2) and tyrosine kinases Janus kinase 1 (JAK1), both of which could 
phosphorylate the potential cytoplasmic transcription factors signal transducer 
and activator of transcription 1 (STAT1) and STAT2 (Levy and Darnell, 2002; 
Stark and Darnell, 2012) (Figure1.2). Tyrosine phosphorylated STAT1 and 2 
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dimerize and translocate to the nucleus, where they bind with IFN-regulator 
factor 9 (IRF9) to form a trimolecular complex termed IFN-stimulated gene 
factor 3 (ISGF3). ISGF3 always binds to its cognate DNA sequences, which 
are known as IFN-stimulated response elements (ISREs). The consensus 
sequence is TTTCNNTTTTC. Further they directly activate the transcription 
of ISGs (MacMicking, 2012). On the contrary, most other cytokines activate 
STAT homodimers that bind to a distinct gamma-activated sequence (GAS; 
consensus sequence: TTCNNNGAA). Therefore, canonical type I IFN 
signaling induces a distinct subset of several hundred ISRE-driven ISGs, and 
most of them could build a cellular antiviral state (Schoggins et al., 2011; 




Figure 1.2 Overview of the IFN receptor signaling pathways 
IFNAR is composed of IFNAR1 and IFNAR2 subunits, which activates JAK1 and 
TYK2 upon binding of IFNs. Subsequently, STAT proteins are recruited, which 
control distinct gene expression processes. ISGF complex binds to ISRE sequences to 
activate typical antiviral genes, while STAT1 homodimers bind to GASs to induce 
pro-inflammatory genes. STAT3 homodimers suppress pro-inflammatory gene 
expression indirectly by binding to co-repressor complex SIN3 transcription regulator 
homologue A (SIN3A). Image taken from Ivashkiv and Donlin, 2014. 
 
1.2.3 Role of type I IFN in cancer 
Type I IFN regulates more than 200 genes such as NF-κB, interferon 
regulatory factor 1 (IRF1), p53, STAT1 and interleukin enhancer binding 
factor 3 (NF-90) which control diverse cell processes such as growth 
(Petryshyn et al., 1984) and differentiation (Meurs et al., 1993) at a 
transcriptional level. Most of these effects contribute to the antiproliferative 
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activity of these cytokines by cell cycle arrest and/or apoptosis (Gil et al., 
1998). IFNα and IFNβ possibly mediate antitumor activity through indirect 
mechanisms by regulation on immunomodulatory and anti-angiogenic 
responses. Type I IFNs can affect immune responses by the effects on myeloid 
(Luft et al., 1998), T and B cells (Le Bon et al., 2001), chemo-kinesis and 
chemotaxis, as well as promote the acquisition of cytotoxic activity of natural 
killer (NK) cells (Lee et al., 2000).  
Another interesting antitumor mechanism of IFNs is the anti-angiogenic 
activity. These cytokines inhibit secretion of angiogenic factors, such as 
vascular endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF-2) 
that produced by tumor cells and regulator of G-protein signaling 5 (RGS5) 
that is a protein involved in angiogenic tumor vasculature (Zhu et al., 2008). 
IFNs have been proposed to be a potential therapy approach to overcome 
multidrug resistance (MDR). Multidrug resistance-associated proteins are 
overexpressed in several aggressive tumors such as pancreatic cancer (Vitale 
et al., 2007).  
As a result of the anti-proliferative and differentiating effects of Type I IFNs, 
IFNα and IFNβ genes may possibly function as tumor suppressor. With 
previous study, there has been an increasing interest in a possible role of IFNα 
in combination with the chemo-radio-immunotherapy in the treatment for 
pancreatic cancer, as shown by several phase II and III trials (Neoptolemos et 
al., 2004). All these studies reported a potential antitumor activity using an 
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IFNα-based chemo/radiation regimen in cancer, but the side effects are still 
unclear. On the contrary, with the detailed study of antitumor effects of IFNα, 
those of IFNβ are not well established. However, IFNβ is significantly more 
effective in vitro than IFNα in inducing cell growth inhibition in both exocrine 
and endocrine tumors of the pancreas and adrenal cancer (Vitale et al., 2006; 
Koetsveld et al., 2006). In these tumors, IFNβ is more potent in inducing both 
apoptosis and cell cycle arrest in late S-phase than IFNα. IFNβ has a higher 
binding affinity than IFNα and has higher synergistic interaction on tumor cell 
growth inhibition when combined with other antitumor agents (Croze et al., 
1996).  
 
1.3 Nucleic acid sensing 
The cellular innate immune system senses and eliminates microbes rapidly in 
a non-specific manner, which consists of different groups of cellular sensors 
(Wu and Chen, 2014). Sensors include the Toll-like receptors (TLRs), retinoid 
acid-inducible gene I (RIG-I)- like receptors (RLRs) and cytosolic nucleic acid 
sensors, in addition to nucleotide-binding and oligomerization domain 
(NOD)-like receptors (NLRs). 
The innate immune response consists of a series of cellular sensors and 
signaling pathways that activates defense mechanisms in response to microbe 
invasion. The innate immune system responds to the presence of pathogens or 
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danger by recognition of pathogen-associated molecular patterns (PAMPs) or 
damage-assoicated molecular pattern (DAMPs) respectively, leading to altered 
gene expression, immune effector mechanisms and ultimately a return to 
homeostasis. PAMPs and DAMPs are detected by several classes of host 
pattern recognition receptors (PRRs) including the Toll-like receptors (TLRs), 
RIG-like receptors (RLRs), NOD-like receptors (NLRs) and C-type lectin 
receptors. 
Many PRRs are able to trigger a TANK-binding kinase 1 (TBK1) and 
interferon regulator factors 3 (IRF3)-dependent type I IFN and cytokine 
response. Recently identified candidate cytosolic DNA sensors include 
Z-DNA-binding protein 1 (ZBP1); absent in melanoma 2 (AIM2); interferon 
gamma inducible protein 16 (IFI16); stimulator of interferon gene (STING); 
DEAD(Asp-Glu-Ala-Asp) box polypeptide 41 (DDX41) and cyclic guanosine 
monophosphate-adenosine monophosphate synthase (cGAS) (Sun et al., 2013; 
Takaoka et al., 2007; Yang et al., 2010; Yanai et al., 2009) IKKε is mainly 
expressed in lymphocytes, while TBK1 is constitutively expressed in 
embryonic and adult fibroblasts (Perry et al., 2004) and is required in these 
cells for normal IRF3 activation and IFN-beta production induced by dsRNA 
(Lam et al.,2014; Hemmi et al., 2004).  
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1.3.1 Cytosolic DNA sensors and tumorigenesis 
IFI16 and AIM2, both of which are cytosolic DNA sensors of the PYHIN 
family, have been proposed to function as tumor suppressor. The PYHIN 
(pyrin and HIN200 domain-containing proteins) family consists of the mouse 
IFN-inducible genes Ifi200, p202a, p202b, p203, p204, myeloid cell nuclear 
differentiation antigen (Mnda1) and Aim2, as well as the human HIN-200 
genes IFI16, MNDA, AIM2 and PYHIN1 (Gariglio et al., 2011). Many 
PYHIN family members were also reported to regulate proliferation, 
differentiation and transcriptional regulation (Asefa et al., 2004; Cresswell et 
al., 2005) 
Overexpression of IFI16 protein in normal human diploid fibroblasts and 
prostate epithelial cells is a link to cellular senescence-associated permanent 
cell growth arrest (Choubey et al., 2008). According with this finding, 
expression of IFI16 was downregulated in breast cancer tissue (Fujiuchi et al., 
2004) and transcriptional silencing of IFI16 by histone deacetylase was found 
in human prostate cancer cell lines (Alimirah et al., 2007). Increased 
expression of IFI16 in cells inhibits cell proliferation by promoting the 
p53/p21- and RB/E2F- mediated inhibition of cell-cycle progression, and 
downregulation of IFI16 could be responsible for oncogenesis (Liao et al., 
2011; Ludlow et al., 2005). Furthermore, IFI16 is reported to have 
anti-tumoral activity by inducing apoptosis of tumor cells in vivo, through 
inhibiting neo-vascularisation, and increasing the recruitment of macrophages 
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(Mazibrada et al., 2010). AIM2 is often mutated in human melanomas, 
colorectal carcinomas, gastric and endometrial cancers (DeYound et al., 1997; 
Michel et al., 2010; Woerner et al., 2007). More studies indicate that 
overexpression of AIM2 suppresses proliferation and promotes the rate of 
apoptosis of several cells, and other members of HIN-200 family of proteins 
have the similar effect (Johnstone and Trapani, 1999; Landolfo et al., 1998). 
AIM2 expression inhibition in human diploid fibroblasts triggers the 
activation of DDR, which implicates a role of AIM2 in the maintenance of 
genomic stability in cells (Duan et al., 2011). Moreover, AIM2 is essential for 
IL-1beta induction by Epstein-Barr virus (EBV) genomic DNA and 
EBV-encoded small RNAs, which inhibits tumor growth and promotes 
survival rates by host responses respectively (Chen et al., 2012). 
 
1.4 Stimulator of interferon genes (STING) 
STING (stimulator of interferon genes) was identified by its ability to trigger 
innate immune gene transcription including the secretion of type I IFN i n 
response to microbial invasion (Ishikawa and Barber, 2008). STING, which is 
also known as TMEM173, MTIA, ERIS and MPYS, is a 379 amino acid 
protein in human cells, comprising several transmembrane regions in its 
N-terminal region, which presents as a dimer in the endoplasmic reticulum 
(ER) (Barber, 2014). STING performs broad anti-pathogen functions, which is 
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independent of the TLR pathway and possibly be evolutionarily conserved, 
with homologs existing in Drosophila. For instance, after DNA virus, 
retrovirus or bacterial infection, STING-dependent signaling is activated when 
nuclear translocation of the transcription factors IRF3, nuclear factor-κB 
(NF-κB) and Jun N-terminal protein kinase/stress-activated protein kinase 
(JNK/SAPK) pathway happens, which facilitates the production of dozens of 
innate and adaptive immune modulatory proteins including pro-inflammatory 
cytokines such as CXCL10 and TNFα (Burdetter and Vance, 2013). According 
to the studies that have been conducted past few years, STING is considered to 
be effectively activated in the presence of cytosolic DNA that are generated 
from DNA viruses or bacteria such as herpes simplex virus 1 (HSV1) or 
Listeria (Sauer et al., 2011). Moreover, STING is able to be stimulated by 
transfected DNA including bacterial genomic DNA, purified viral DNA, 
plasmid DNA, calf thymus DNA, and synthetic double-stranded DNA 
(dsDNA) bound with cationic liposomes (Ishikawa et al., 2009). Such ligands 
cannot induce type I IFN secretion, as well as other innate immune proteins in 
Sting-deficient fibroblasts, conventional dendritic cell and macrophages, 
which suggests the core role of STING in innate immune system (Ishikawa et 
al., 2009). 
Although it is reported that STING can directly bind to dsDNA species, its 
affinity is very low in mammalian cells (Civril et al., 2013). The search for 
DNA sensors that could facilitate STING activity led to the discovery of cyclic 
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GMP-AMP synthase (cGAS) that generates the cyclic dinucleotide (CDN), 
cyclic GMP-AMP (cGAMP) from GTP and ATP in a DNA-dependent manner 
(Sun et al., 2013; Burdette et al., 2011). In human cells, cGAS catalytic 
activity could be activated by sequence non-specific dsDNA greater than 45 
base pairs. In mammalian cells, cGAS generated cGAMP binds to STING 
dimers on the ER to initiate innate immune gene production, but the 
mechanism is still unclear (Cai et al., 2014). In bacteria, cyclic di-AMP and 
cyclic di-GMP are secreted and function as ubiquitous second messengers to 
trigger a spectrum of responses to internal and external stimuli  (Woodward et 
al., 2010). These CDNs can activate directly in the same way as cGAMP. 
Moreover, cGAS-deficient mice showed similar phenotypes to STING 
deficient mice in susceptibility to DNA pathogen infection and essentials for 
IFN production upon dsDNA treatment (Li et al., 2013). Activation of STING 
by DNA viruses induces trafficking from the ER area through the Golgi 
apparatus to perinuclear regions via a mechanism resembling non-canonical 
autophagy. This processing includes STING escorting TBK1 to endosomal or 
lysosomal regions, which likely harbor the transcription factors IRF3 and 
NF-κB (Ishikawa et al., 2009) (Figure 1.3).  
Observing that activation of STING can induce potential innate immune 
transcriptional events has led to evaluation of whether ligands that activate 
STING signaling pathway could be useful as potent adjuvants in anti-pathogen 
and vaccine related strategies (Coban et al., 2013; Lemos et al., 2014). It is 
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worth to note that STING signaling has been shown to be important for the 
adjuvant effects of plasmid-based DNA vaccines (Ishikawa et al., 2009). For 
instance, mice lacking STING does not generate an adaptive immune 
responses to DNA vaccines. Hence, understanding the STING pathway 
possibly leads to the new generation of more effective and safe DNA-based 
plasmid immunization regimes. Moreover, it is reported that in Sting-deficient 
mice, host antitumor T cell responses was lost and rejection of immunogenic 
tumors was ablated. However, recently study revealed that STING deficient 
mice were resistant to 7,12-dimethylbenz(a) anthracene (DMBA) skin 
tumorigenesis (Ahn et al., 2014), which may suggest a role of facilitating 
tumorigenesis of STING in cancer. Further research of positive and negative 
regulation of the STING pathway and the role of STING plays in the cancer 
context should lead to new therapeutic strategies against cancer. In particular, 
STING agonists could be considered for a potential therapy target.  
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Figure 1.3 Overview of cGAS-STING pathways 
Cytosolic DNA activates cGAS to form a cGAS-DNA complex with formation of 
2’3’-cGAMP from ATP and GTP. 2’3’-cGAMP further binds and activates STING 
through structural activates. Activated STING phosphorylate IRF3 by recruitment of 
TBK1. IRF3 subsequently translocates into nucleus along with NF-κB to induce type 
I IFNs and other cytokines production. Image taken from Cai et al., 2014. 
 
1.5 Clustered regularly interspaced short palindromic repeats (CRISPR) 
A number of genome editing technologies have emerged in recent years, 
including zinc-finger nucleases (ZFNs) (Porteus and Baltimore, 2003), 
transcription activator-like effector nucleases (TALENs) (Zhang et al., 2011) 
and the RNA-guided CRISPR-Cas nuclease system (Deveau et al., 2010; 
Horvath et al., 2010). While ZFN and TALEN are used as strategies of 
tethering endonuclease catalytic domains to modular DNA-binding proteins 
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for inducing targeted DNA double-strand breaks (DSBs) at specific genomic 
loci. In CRISPR, a nuclease called Cas9 is guided by small RNAs through 
Wastson-Crick base pairing with target DNA (Garneau et al., 2010; Jinek et al., 
2012) (Figure 1.4). CRISPR is a system that is significantly easier to design, 
highly efficient and specific and well suited for multiplexed gene editing for a 
variety of cell types and organisms. 
Cas9 promotes genome editing by stimulating a DSB at a target genomic locus 
efficiently (Urnov et al., 2010; Hsu et al., 2012). Upon cleavage by Cas9, the 
target locus usually undergoes two major pathways for DDR: the error-prone 
NHEJ or the high-fidelity HDR pathway, both of which can be employed to 
achieve an expected editing outcome. In the absence of a repair template, 
DSBs are reconnected through the NHEJ process, which leaves scars in the 
form of insertion or deleting mutations. NHEJ can be useful to mediate gene 
knockouts, as deletion happening within a coding exon can lead to reading 
frame shift mutations and premature stop codons (Perez and Zhang, 2012). 
Multiple DSBs can be exploited to mediate larger deletions in the genome. 
HDR is an alternative major DNA repair pathway. HDR typically happens at 
lower and substantially more variable frequencies than NHEJ, but it can 
generate precise, defined modifications at a target locus in the presence of an 
exogenously introduced repair template. Unlike NHEJ, HDR is commonly 
active only in dividing cells, and its efficiency varies widely depending on the 
cell type and state, as well as the genomic locus and repair template 
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(Saleh-Gohari and Heeleday, 2004). 
 
1.5.1 Overview of the CRISPR-Cas system 
CRISPR-Cas is a microbial adaptive immune system that employs 
RNA-guided nucleases to cleave foreign genetic species (Deveau et al., 2010). 
There are three types (I-III) of CRISPR systems have been discovered and 
identified among a wide range of bacterial and archaeal hosts. Each system 
comprises a cluster of CRISPR-associated (Cas) genes, noncoding RNAs and 
a distinctive array of repetitive elements (direct repeats). These repetitive 
elements are interspaced by short variable sequences derived from exogenous 
DNA targets known as protospacers, and they constitute the CRISPR RNA 
(crRNA) array together (Makarova et al., 2011) Within the DNA target, each 
protospacer is associated with a protospacer adjacent motif (PAM), which can 
vary depending on the specific CRISPR system (Marraffini and Sontheimer, 
2008; Brouns et al., 2008). 
In this study, the type II CRISPR system was employed. Type II CRISPR 
system includes the nuclease Cas9, the crRNA array encoding the guide RNAs 
(gRNAs) and a required auxiliary transactivating crRNA (tracrRNA) that 
facilitates crRNA array processing into discrete units (Garneau et al., 2010). 
Each crRNA contains a 20-nt guide sequence and a partial direct repeat, where 
the former sequence leads Cas9 to 20-bp DNA target by Watson-Crick base 
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pairing (Figure1.4). In this system, the target DNA must precede a 5’-NGG 
PAM, where as other Cas9 orthologs may have different PAM requirements, 
such as those of S. thermophiles (5’-NNAGAA for CRISPR1 and 5’-NGGNG 
for CRISPR 3) and Neisseria meningiditis (5’-NNNNGATT) (Cong et al., 
2013; Garneau et al., 2010). 
The CRISPR-Cas RNA-guided nuclease function is reconstituted in 
mammalian cells by the heterologous expression of human codon-optimized 
Cas9 and the requisite RNA components (Cho et al., 2013). Moreover, the 
crRNA and tracrRNA can be formed to a fusion to create a chimeric, 
single-guide RNA (sgRNA) (Jinek et al., 2012). Cas9 can thus be redirected 
toward nearly any target of interest in vicinity of the PAM sequence by 
altering the 20-nt guide sequence within the sgRNA (Jinek et al., 2012). Due 
to its ease of implementation and multiplexing capacity, Cas9 has been used to 
generate engineered eukaryotic cells carrying specific mutations via both 
NHEJ and HDR (Hwang et al., 2013). Direct injection of sgRNA and mRNA 
encoding Cas9 into embryos has enabled the rapid generation of transgenic 
mice with multiple modified alleles (Wang et al., 2013; Shen et al., 2013). 
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Figure 1.4 Overview of CRISPR-Cas9 system 
Cas9 nucleases (yellow) are targeted to genomic DNA by an sgRNA consisting of 20 
nucleotides length guide sequence (blue) and a scaffold (red). The guide sequence 
pairs with target DNA (blue bar), where upstream of a requisite 5’-NGG adjacent 
motif (pink) directly. Cas9 mediates a double strand break 3bp upstream of PAM (red 
triangle). Image taken from Ran et al., 2013. 
 
1.6 Aims 
Previous report indicated that STING is highly mutated in cancers suggesting 
a role for STING in cancer (Sauer et al., 2011). The aim of this project was to 



























A549 and HeLa cells were cultured in DMEM (Invitrogen, Singapore) 
supplemented with 10% FCS (Hyclone, USA), and 1% pen/strep (Invitrogen, 
Singapore). Wild type (WT) HCT116 cell lines were a generous gift from K. 
Miyagawa (Hiyama et al., 2006). Cells were cultured in McCoy (Invitrogen, 
Singapore) supplemented with 10% FCS (Hyclone, USA) and 1% pen/strep 
(Invitrogen, Singapore). FCS was heat inactivated for 30 mins at 50°C before 
addition to cell culture media. All cells were grown at 37C in a humidified 5% 
CO2 incubator (Thermo Scientific, Singapore). 
Western Blot 
Whole cell extracts were prepared from purified cells from different cell lines 
and electrophoresis in 10% SDS-PAGE gels, and blotted onto nitrocellulose 
membranes (BioRad). For the preparation of whole-cell extracts, cells were 
lysed in Radio-Immunoprecipitation Assay (RIPA) buffer consisting of 
150mM NaCl, 1mM EDTA, 50mM Tris-HCL (pH7.4), 1% NP-40 and 1% 
sodium deoxycholate (Sigma). In addition, protease inhibitor cocktail set III 
and phosphatase inhibitor cocktail set V (Merck Millipore, Germany) were 
added to the lysis buffer according to the manufacturer’s instructions. 
Antibodies and GAPDH (Sigma) specific antibodies and horseradish 
peroxidase-coupled second stage reagents were used to develop the blots 
(Thermo). Blots were exposed on X-ray film (Fuji), and densitometry analysis 
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was performed using ImageJ 1.46. Analysis of blots was done by MetaMorph, 
which is a professional software for imaging analysis. 
Reagents 
Aphidicolin, Ara-C and dimethyl sulfoxide (DMSO) were purchased from 
Sigma (Singapore); cyclic dinucleotides (CDNs) were purchased from 
Invivogen;  
 
Transfection and Transduction 
For transfection and transduction, retroviral supernatants were generated as 
described (Diefenbach et al., 2003). Briefly, to prepare retroviruses, 293T cells 
were transfected with: 1) retroviral MSCV-GFP vectors 2) packaging plasmids 
encoding structural proteins of retroviruses, env, gag and pol contained in pFB 
vector along with 3) Transfectin (Biorad, USA). Transfection was performed 
in a 6-well plate and left to incubate at 37°C for 48 h. Cell culture media was 
changed 4 h after transfection. The retroviral supernatant generated after 48 h 
was passed through a 0.45 m filter (Satrorius Stedium, Germany) into target 
cells for transduction. Cells were spun at 2,000 rpm for 90 mins at 34°C. Upon 
48 h after transduction, the top 10% of GFP-positively expressing cells were 
sorted using MoFlo sorter (Beckman Coulter, USA) and subsequently 
expanded for experiments, microscopy, real-time PCR or ELISA. 
Generation of STING knockout cell lines 
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STING knockouts were generated in A549, HeLa and HCT116 Cell lines 
using the CRISPR/Cas9 system. Target gRNA expression constructs were 
selected from human gene database containing target RNA sequences listed in 
Table S1 cloned into gRNA cloning vector (Addgene). 8 x 106 cells were 
transfected with 6 μg Target gRNA and 6 μg pSpCas9(BB)-2A-GFP (Addgene) 
in a 10 cm tissue culture-treated plate. 36 h post-transfection, cells were 
single-cell sorted into 96-well tissue culture-treated plates and allowed to grow 
up about 2 weeks. The following primers were used: STING-5’: 
tttcttggctttatatatcttgtggaaaggacgaaacaccgcgggccgaccgcatttggg; STING-3’: 
gactagccttattttaacttgctatttctagctctaaaaccccaaatgcggtcggcccgc 
Quantitative Real Time PCR 
Total RNA was isolated using the Nucleospin RNA II kit according to 
manufacturer's instructions (Macharey Nagel, Germany) and reverse 
transcribed using M-MLV Reverse Transcriptase (Promega, USA) with 
random primers (Promega, USA). The total reaction was 25 μl made up of 
reverse transcribed RNA, 0.2 μM forward primer, 0.2 μM reverse primer and 
12.5 μl of iTaq SYBR Green Supermix with ROX (Bio-Rad, Singapore). 
Triplicates were performed for the PCR reaction using the ABI PRISM 7700 
Sequence Detection System (Applied Biosystems, Singapore). The 
thermocycling parameters were 50°C (2 min), 95°C (3 mins) followed by 40 
cycles of 95°C (15 sec), 60°C (30 sec) and 72°C (45 sec). Finally, samples 
were normalized to the signal generated using housekeeping gene HPRT. 
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Samples prepared without total RNA was served as negative controls. The 
following primers were used: HPRT-5’: gctataaattctttgctgacctgctg; HPRT-3’: 
aattacttttatgtcccctgttgactgg; STING-5’: ggctttagccgggaggatag; STING-3’: 
gcaggttcctggtaggcaa; IFNα4-5’: agaggccgaagttcaaggtta; 
IFNα4-3’:tgtgggtctgaggcagatca; IFNβ-5’: aaactcatgagcagtctgca; IFNβ-3’: 
aggagatcttcagtttcggagg. Two-tailed unpaired t-test (GraphPad) was applied for 
statistical analysis. P<0.05 denotes significance. 
Microscopy 
For PicoGreen staining, cells were treated with 6 μM PicoGreen (Life 
technology, Singapore) for 1-2 h at 37°C. After treatment, cells were fixed 
with 4% formaldehyde for 10 mins. And then, cells were washed with PBS 
three times before addition of 2 mg/ml of RNase A (Sigma, Singapore) for 1 h 
at 37°C to ensure that only DNA-specific signals are observed. Slides were 
washed once in PBS before mounting with Dako fluorescent mounting 
medium (Dako, UK). 
For DNA antibody staining, cells were fixed with 4% formaldehyde for 10 
mins. DNA was denatured using 50% Formamide (VWR International, USA) 
in PBS for 10 min at room temperature followed by incubation for 20 min at 
75°C. Cells were washed with PBS three times before addition of 2 mg/ml of 
RNaseA (Sigma, Singapore) for 1 h at 37°C to ensure that only DNA-specific 
signals are observed. For double-stranded DNA (dsDNA) staining, the 
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controls included pretreatment with 100 U/ml DNase (Sigma, Singapore) for 1 
h at 37°C. Cells were washed with PBS and blocked with 1% BSA in PBS for 
1 h. For ssDNA stainings, some cells were incubated with 200 U/ml S1 
nuclease (Thermo Fisher Scientific) for 1 h at 37°C. After washing with PBS, 
cells were stained with ssDNA (clone F7-26, Merck) or dsDNA (MAB1293, 
Merck)-specific antibodies, followed by anti-mouse IgG coupled to Cy3 
(AP124C, Merck), or anti-mouse IgM coupled to Cy3 (AP128C, Merck) 
antibodies. Stained cells were stained with DNA fluorochrome DAPI (0.5 
μg/ml in PBS, #71-03-01, KPL Inc., USA) for 10 min. Slides were washed 














STING Regulates Levels of 











3.1 Generation of STING knock out (KO) cells 
STING was previously shown to be crucial in type I IFN mediated signaling 
pathway (Lemos et al., 2014). We therefore investigated the role of STING in 
different cancer cells. Firstly, we employed CRISPR to knock out STING in 
cancer cells to generate STING-deficient cells. Cas9-GFP plasmid and 
CRISPR construct plasmid were co-transfected into A549, HeLa and HCT116 
cells. After 24 hours, GFP positive cells were single cell sorted into 96-well 
plates. Protein lysate was extracted from cell cultures derived from sorted cells. 
No STING was detected in some of the sorted cells (Figure 3.1a). Furthermore, 
STING signals were not observed in the same STINGCRISPR cells when 
analyzed by confocal microscopy (Figure 3.1c). In summary, our data show 














Figure 3.1 Generation of STING deficient cells by CRISPR. 
(a) Western blot analysis of A549, HeLa and HCT116 cells transfected with control or 
STING-specific CRISPR constructs. Immunoblots were probed with antibodies 
specific for STING and GAPDH; (b) Quantification of relative STING expression. 
Intensities of STING bands were determined by Metamorph and normalized to 
GAPDH levels and relative STING levels in control transfected cells. ***p<0.005; (c) 
Control and STING CRISPR transfected A549, HCT116 and HeLa cells were stained 








3.2 Decreased levels of cytosolic DNA in STING-deficient A549 cells 
To test whether the presence of STING affects the accumulation of cytosolic 
DNA, we stained cells with antibodies specific for ssDNA, dsDNA and 
DNA:RNA hybrids. Surprisingly, we found that the levels of cytosolic DNA 


















Figure 3.2 STING deficiency decreases the levels of cytosolic DNA in cancer 
cells. 
(a) WT and STING deficient cells were stained with 6 μM dsDNA-specific vital dye 
PicoGreen for 2 hours; (b) A549 cells and A549 STING KO cells were stained with 
dsDNA, ssDNA or DNA:RNA hybrid (S9.6)-specific antibodies. Cells in the 
indicated panels were treated with 2 mg/ml RNaseA for 1 hour before staining. 
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3.3 The levels of cytosolic DNA do not increase in STING-deficient cells in 
response to DNA damage 
We previously found that levels of ssDNA and dsDNA increased in the cytosol 
after treatment with the genotoxic agent Ara-C (Lam et al., 2014). However, 
we observed that STING-deficient cancer cells failed to accumulate cytosolic 
DNA in response to Ara-C (Figure 3.3). The result suggests a key role of 









Figure 3.3 The levels of cytosolic DNA do not increase in STING-deficient cells in 
response to Ara-C.  
A549, HCT116 and HeLa cells were stained with 6 μM dsDNA-specific vital dye 
Picogreen for 2 hours (green) after 10 μM Ara-C treatment or DMSO treatment for 
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4.1 STING deficiency decreases the level of Type I IFNs in cancer cells 
Type I IFNs play a critical role in a range of immune responses, including the 
promotion of antitumor activity (Cho and Kelsall, 2014). STING is reported to 
be crucial for type I IFN expression in normal cells, hence we analyzed if 
STING contributes to the expression of type I IFN in cancer cells. As shown in 
Figure 4.1, there was a significant decrease in type I IFNs expression level in 
STING deficient cells. IFNα4 and IFNβ were downregulated by 8.3 and 
19.2-fold in A549 STING KO cells, and 5.6 and 7.7-fold in HCT116 STING 
KO cells respectively. The results suggest that STING is an important 
regulator of type I IFN expression in cancer cells. 
Figure 4.1 STING contributes to type I IFN expression in cancer cells. 
Relative IFNα4 and IFNβ transcriptional levels in WT (black column) and 
STING-deficient (grey column) A549 and HCT116 cells were measured by 
quantitative real-time PCR. Data are mean +/- standard deviation of biological 




4.2 The levels of type I IFNs do not increase in STING-deficient cells in 
response to DNA damage 
We previously found that DNA damaging agents such as aphidicolin induce 
significant secretion of type I IFNs. We therefore investigated whether the 
increase of type I IFN in response to DNA damage depends on STING. We 
treated WT and STING-deficient cells with aphidicolin for 6 hours, and 
analyzed type I IFNs expression level. After 10 μM Aphidicolin treatment, 
IFNα4 was upregulated by 6.3 and 7.4-fold, while IFNβ was upregulated by 
6.8 and 5.3-fold respectively compared to DMSO treatment (Ctrl). However, 
there was no significant change of type I IFNs expression in STING-deficient 
cells (Figure 4.2). The levels of type I IFNs do not increase in 
STING-deficient cells, while increased significantly in WT cells in response to 
Aphidicolin. This result suggests that type I IFNs secretion is induced by DNA 





Figure 4.2 The levels of type I IFNs do not increase in STING-deficient cells in 
response to aphidicolin. 
Relative IFNα4 and IFNβ transcriptional levels in WT (black column) and 
STING-deficient (grey column) A549 and HCT116 cells were measured by 
quantitative real-time PCR. Data are mean +/- standard deviation of biological 
















4.3 Exogenous dsDNA does not induce type I IFNs expression in STING 
deficient cells 
DNA damaging agents induce the presence of cytosolic DNA (Lam et al., 
2014). Cytosolic DNA triggers the innate immune response leading to type I 
IFN expression (Cho & Kelsall, 2014). Consistent with previous reports, we 
found that STING is required for the expression of type I IFNs in A549 and 
HCT116 cells as WT, but not STING-deficient cells in upregulation of type I 
IFNs upon transfection of DNA. Hence, these results also confirm that we 
successfully generated STING-deficient cells. 
 
Figure 4.3 The levels of type I IFNs do not increase in STING-deficient cells in 
response to transfection of DNA. 
Relative IFNα4 and IFNβ transcriptional levels in WT (black column) and 
STING-deficient (grey column) A549 and HCT116 cells were measured by 
quantitative real-time PCR. Data are mean +/- standard deviation of biological 
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Can Trigger Type I IFNs 










5.1 The levels of type I IFNs do not increase in respond to dsDNA 
transfection in 293T cells. 
A recent report indicates that type I IFN pathway is blocked by a splice variant 
of STING, which is termed as MITA-related protein (MRP), in 293T and 
HeLa cells, while 293T and HeLa cells can express endogenous STING.  
(Chen et al., 2014). Therefore, we analyzed the levels of type I IFNs upon 
dsDNA transfection in these two cell lines. The levels of type I IFNs increased 
significantly in respond to dsDNA transfection in HeLa cells, but not in 293T 
cells (Figure 5.1). After dsDNA transfection for 6 hours, IFNα4 and IFNβ 
transcript levels were upregulated by 13.6 and 15.8-fold respectively in HeLa 
cells. However, there was no significant change of type I IFNs expression in 
293T cells. These results suggest that dsDNA cannot induce type I IFN 






Figure 5.1 dsDNA transfection induces type I IFN production in HeLa cells but 
not 293T cells. 
Relative IFNα4 and IFNβ transcriptional levels in WT (black column) and 
STING-deficient (grey column) 293T and HeLa cells were measured by quantitative 
real-time PCR. Data are mean +/- standard deviation of biological replicates. 
























5.2 CDNs induce the expression of type I IFNs in 293T cells 
CDNs are ubiquitous second messenger molecules used in bacterial signal 
transduction and act as defense triggers in mammalian cells (Wu et al., 2013). 
Upon bacterial infection, CDNs are released in the cells to activate STING and 
type I IFN production. Cyclic diguanylic acid (c-di-GMP) is the most 
prevalent intracellular signaling intermediate in bacteria. Other important 
CDNs include cyclic diadenylic acid (c-di-AMP) and cyclic adenylicguanlic 
acid (cGAMP). In this study, we used 2’ 3’-cGAMP to investigate if MRP 
blocks type I IFN response. Surprisingly, 293T cells secret type I IFN upon 
stimulation with CDNs. After CDNs treatment for 6 hours, IFNα4 and IFNβ 
was upregulated by 16.7 and 20.3-fold respectively. However, there was no 
significant change of type I IFNs expression after transfection of dsDNA. 
These results suggest that CDNs can trigger type I IFN pathway in 293T cells, 




Figure 5.2 CDNs but not dsDNA induce type I IFNs expression in 293T cells. 
Relative IFNα4 and IFNβ transcriptional levels in 293T cells were measured by 
quantitative real-time PCR in response to dsDNA (light grey) and CDNs (deep grey). 























5.3 CDNs induce the presence of cytosolic DNA in cancer cells in a 
STING-dependent manner 
To further investigate the reason for type I IFN activation by CDNs, we 
analyzed changes that cells respond to CDNs. By staining with antibody 
specific against dsDNA, we found that CDNs increase the levels of cytosolic 
dsDNA in the cytosol. However, in STING-deficient cells, the levels of 
cytosolic DNA did not increase in response to CDNs stimulation (Figure 5.3). 
These results suggest that the presence of cytosolic DNA is induced in a 
STING-dependent manner by CDNs. 
 
Figure 5.3 CDNs induce the presence of dsDNA in the cytosol of cancer cells. 
WT and STING-deficient A549 and HCT116 cells were stained with dsDNA specific 
antibodies (red) and DAPI (blue) after treatment with 1 μg/mL CDNs for 16 hours. 
Cells were treated with 2mg/ml RNaseA for 1 hour before staining with 







Chapter 6  












6.1 Summary of key findings 
In the present study, we investigated the role of STING in cancer cells. Our 
results show that STING may regulate the presence of cytosolic DNA. 
Furthermore, we provide evidence that STING is important for the constitutive 
low expression of type I IFNs cancer cells.  
To investigate the link between STING and type I IFNs pathway, we used 
293T cell line, of which type I IFNs are reported to be blocked by 
MITA-related protein (MRP). By stimulation of CDNs, we found that the 
levels of type I IFNs increased significantly comparing with dsDNA 
stimulation in 293T cells. Our findings suggest that type I IFNs pathway is not 
blocked in cancer. In summary, our study reveals a novel role for STING in 
cancer innate immunity. 
 
6.2 Regulation of expression of type I IFN by STING in cancer cells 
6.2.1 Regulation of type I IFNs production by STING 
Previously, we found that genotoxic stress induces type I IFNs activates 
immune responses (Bist et al., 2013). Given that genotoxic stress is highly 
related to infections and cancer, our findings suggested a new mechanism for 
the regulation of immune system such as type I IFNs pathway in cancer cells. 
It is reported that STING is an important regulator for type I IFNs expression 
under DNA damage, but the details are remaining unclear. 
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Here we investigated the role of STING, which is a core cytosolic DNA sensor 
that can recognize cytosolic DNA and RNA introduced by microbes or viruses 
(Palm and Medzhitov, 2009). Previous studies provide evidence that DDR 
could activate STING expression, therefore induces IRF3 phosphorylation and 
type I IFNs production (Burdette and Vance, 2013), but the details of these 
processes need to be investigated. 
The DDR was found to be constitutively activated in many cancer cell and 
precancerous tumor samples (Weber & Ryan, 2014). Consistent with these 
findings, we found that Yac-1 tumor cells contain detectable cytosolic DNA 
and exhibit constitutive activation of STING/TBK1/IRF3 (Lam et al., 2014). 
Cancer cells express relatively low level of type I IFNs with the activation of 
STING/TBK1/IRF3, which might be due to STING mutations reported to be 
prevalent in many cancer cells. 
As previously reported, STING was found to be mutated in many cancer cells 
(data not shown). For that reason, we characterized the role of STING in 
cancers. An interesting finding in our lab was that cells subjected to DNA 
damaging agents can accumulate DNA in the cytosol, which suggests that 
cytosolic DNA is a possible trigger for DNA damage-dependent activation of 
TBK1/IRF3 and ultimately the production of type I IFNs (Lam et al., 2014). It 
is well established that DNA sensor pathways can activate STING/TBK1/IRF3 
pathway (Stetson and Medzhitov, 2006). Strikingly, our data suggest that the 
production of type I IFNs critically depends on STING. Hence, DNA sensors 
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that activate STING, such as cGAS are possibly required for constitutive type 
I IFN expression as well as type I IFN response to DNA in cancer cells. How 
DNA damage and the DNA damage response affect the DNA accumulation in 
cell cytosol and the following biological response remains to be clarified and 
elucidated in more details. It is possible that DNA repair of genomic DNA 
damage leads to the presence of cytosolic DNA. 
It remains unclear how STING is activated in response to DNA damage. It is 
possible that the DDR contributes more directly to STING activation by 
phosphorylating important residues in these molecules. Atm-deficient mice 
prime the type I IFN response via the STING pathway, and loss of ATM leads 
to the presence of cytosolic ssDNA (Härtlova et al., 2015). It is possible that 
CHK1 or other DDR effector kinases downstream of ATR play a crucial role 
in STING activation. Our finding shows that STING may regulate the 
presence of cytosolic DNA, and more details need to be established of the link 
between cytosolic DNA, STING and type I IFNs in cancer cells. 
Taken together, DNA damage in cancer cells can lead to the presence of 
cytosolic ssDNA, dsDNA and DNA:RNA hybrids. These cytosolic nucleic 
acids are recognized by DNA sensor pathways that activate 
STING-TBK1-IRF3 pathway and initiate an innate immunity response. 
6.2.2 Nature of cytosolic DNA in tumor cells 
Cytosolic DNA has been shown to accumulate in cells under viral and 
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bacterial infection or uptake of apoptotic host cells (Ishii and Akira, 2006). We 
found the presence of different kinds of cytosolic DNA presence in uninfected 
human tumor cells. Firstly, an interesting question is where cytosolic DNA 
originates from and the how cytosolic DNA accumulates in tumor cells. 
There are several studies that report the release of mitochondria DNA 
(mtDNA) in the cytoplasm upon cellular stress, which is a possible source for 
cytosolic DNA accumulation. During apoptosis, the secretion of oxidized 
mtDNA could activate NLRP3 inflammasome, leading to the production of 
IL-1β. IL-5 or IFN-γ primed eosinophils could release mitochondrial DNA on 
reactive oxygen species dependent manner, but independent of eosinophil 
death and the release of DNA happened rapidly in a catapult-like manner 
(Yousefi et al., 2008). Neutrophils were also found to release mitochondrial 
DNA in a similar way. However, it is unclear if mtDNA includes dsDNA, 
ssDNA and DNA: RNA hybrids present in the cytosol. 
One possible explanation is that cytosolic DNA is derived from genome. Our 
lab previously provided evidence that cytosolic DNA in mice cells is derived 
from genomic DNA (Shen et al., 2015). Our data indicate that cytosolic 
dsDNA is generated during the DDR-dependent DNA repair of retroelements  
(Hedges and Deininger, 2007). Retroelements, inverted repeats and long 
tandem repeats can result in replication fork stalling and homologous 
recombination that can result in deletion of genomic DNA. 
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It is interesting to investigate more details about the role of cytosolic DNA in 
cancer cells. In HEK293T cells, it is reported that the endogenous expression 
of MITA-related proteins (MRP) will affect STING normal function, and 
further block the type I IFN response upon DNA infection. However, we 
found that 293T cells are able to secrete type I IFNs upon the stimulation of 
cyclic denucleotides (CDNs), which are ubiquitous second messenger 
molecules that can directly bind to and activate STING. This result suggests 
that cytosolic DNA in 293T cells fails to activate spontaneous type I IFN 
mediated signaling pathway. One possible explanation is cytosolic DNA in 
infected cells is different from cancer cells that cannot be detected by cGAS to 
trigger the STING pathway. It would be interesting to elucidate the difference 
between cytosolic DNA in cancer cells and infected cells, which may provide 
a potential cancer therapeutic pathway.  
Recognition of DNA in the cytoplasm happens in a sequence independent and 
length dependent manner (Hornung and Latz, 2010). However, DNA sequence 
may possible affect the level of induction of type I IFNs. The homo-copolymer 
poly (dA:dT) was found to be the strongest activator of IRF3 transcription 
while other homo-copolymers such as poly (dG:dC) or poly (dI:dC) were 
much less potential IFN inducers (Ishii et al., 2006). Thus, the study of length 
and sequence of cytosolic DNA might provide insights into the difference in 
cancer cell cytosolic DNA and the efficiency of STING activation. 
DNA isolated from viruses, bacteria or mammals appears to be recognized 
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equally well when transfected into responsive cells, as long as the DNA 
fragments have sufficient length (Ablasser et al., 2009). The characterized 
cytosolic DNA sensors have been reported to bind DNA directly; however, the 
binding specificities and affinities of only few putative sensors have been 
determined. Crystal structure of the IFI16 HINb domain was found to be 
sequence independence of DNA recognition when forming a complex with 
DNA, and the binding occurs at the sugar-phosphate backbone of DNA 
specifically (Jin et al., 2012). Another example is cGAS, which has a similar 
sequence-independent interaction in the structure (Civril et al., 2013). 
However, further study need to be conducted to establish more details about 
dsDNA fragments, such as the minimum length and why a minimum length of 
dsDNA fragments are needed to induce a type I IFN response in cells. 
Beside viral infection, nucleic acids are described to be key activators for the 
innate immunity systems in several situations. Intracellular DNA is a crucial 
PAMP during intracellular bacterial infection, such as Listeria monocytogenes 
(Rathinam et al., 2010), Mycobacerium tuberculosis (Manzanillo et al., 2012), 
protozoan Plasmodium falciparum (Sharma et al., 2011), and Franscisella 
tularensis (Atianand et al., 2011). Moreover, in autoimmune diseases, for 
example SLE, DNA can also act as endogenous signal during conditions of 
sterile inflammation (Ablasser et al., 2013). DNA from dead cells which is not 
effectively diminished by DNases, such as DNase I in the extracellular space, 
DNase II in lysosomes and three prime repair exonuclease 1 (TREX1) in the 
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cytoplasm, can trigger DNA sensing pathways. Similar with other DNA, DNA 
from dying cells can act as a ‘danger’ signal in immune response to the 
vaccine adjuvant alum (Marichal et al., 2011). Similarly, our data suggests that 
presence of cytosolic DNA in tumor cells is important for the constitutive 
expression of type I IFN and may act as an endogenous DAMP. 
 
6.2.3 Role of STING in cancer 
STING is a 379 amino acid transmembrane containing protein that resides as a 
dimer in the endoplasmic reticulum (ER) of epithelial, endothelial cells as well 
as a variety of hematopoietic cells such as macrophages and dendritic cells 
(DCs) (Konno & Barber, 2014). STING has been found to be essential for 
triggering the production of various cytokines including type I IFNs in 
response to the detection of pathogen related dsDNA in the cytosol of the cells, 
or CDNs such as cyclic di-AMP produced from intracellular bacteria. 
Moreover, it has recently been reported that STING could possibly be 
responsible for causing many auto-inflammatory diseases, such as systemic 
lupus erythematosus (SLE) by becoming activated by intracellular DNA. 
However, mammalian STING is known to weakly bind to dsDNA species but 
can be strongly activated by CDNs that are generated from bacteria such as 
Listeria monocytogenes (Witte et al., 2012). The other type of CDN is 
non-canonical CDNs, such as cyclic di-GMP-AMP, which are generated under 
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the presence of ATP and GTP (Burdette et al., 2011). These CDNs can bind to 
STING dimers and activate STING-TBK1 pathway, which is a 
autophagy-related trafficking from ER to lysosomal/endosomal perinuclear 
regions that contain transcription factors IRF3 and NF-κB (Ishikawa et al., 
2009). STING functions as an adaptor and key sensor in the DNA induced 
type I IFN response. STING is shown to play a pivotal role in controlling a 
variety of inflammation-driven biological activities, and possibly control 
MyD88-dependent carcinogen-induced skin cancer. Recently study revealed 
that STING deficient mice developed colonic tumors at a higher frequency 
compared to normal mice (Ahn et al., 2015). However, the role of STING in 
tumorigenesis has not been elucidated, but STING was found to contribute to 
apoptosis and inhibition of B cell lymphoma cells proliferation, and STING 
has been shown to be responsible for triggering vascular and pulmonary 
syndrome. Given the crucial role of STING in type I IFN mediated signaling 
pathway in a variety of DNA virus infection, STING shows a potential to act 
as a tumor suppressor by preventing infection of cells by oncoviruses (Heiber 
and Barber, 2012). 
By generating STING deficient cancer cells, we investigated the role of 
STING in regulating the expression of type I IFNs. As mentioned in the 
introduction, type I IFN was reported to play in important role in 
immunosurveillance of tumors (Woo et al., 2015). Our data suggest that 
deficiency of STING blocks type I IFN expression in response to transfected 
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DNA. Strikingly, STING also plays an important role in the regulation of type 
I IFNs expression in cancer cells. Further experiments are needed to 
investigate and establish the role of STING in cancer. A possible experiment 
could be to cross Sting-deficient mice to Eu-Myc mice, a mouse model for 
B-cell lymphoma and analyze the cytokines expression levels. 
We found the lower cytosolic DNA presence in STING deficient cancer cells. 
Given the importance of cytosolic DNA presence in cancer and DNA damage 
response, the reason for its decrease need to be further studied. A possible 
explanation is STING can stabilize the existence of different kind of cytosolic 
DNA, so STING deficiency leads to cytosolic DNA degradation. To 
understand this, a chromatin immunoprecipitation (ChIP) for STING can be 
applied. And the result will help us to understand more details of cytosolic 
DNA, such as the sequence and structure. 
Several articles reported that an alternatively spliced isoform of STING, which 
is termed as MITA-related protein (MRP), had been identified in HeLa cells 
and HEK293T cells (Chen et al., 2014). The first 253 amino acids portion of 
MRP is identical to MITA, containing the dimerization domain but lacking the 
TBK1-binding domain. MRP acts dominantly as a dominant negative mutant 
of MITA and blocks STING-mediated IFN induction by TBK1-IRF3 by 
disrupting the STING-TBK1 interaction (Chen et al., 2014). This finding 
provides a new insight for STING regulation on type I IFN signaling in cancer. 
To investigate more details about the role of MRP in the STING pathway, we 
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analyzed the level of type I IFNs in 293T cells upon the stimulation of CDNs 
and dsDNA. However, we found that 293T cells secrete type I IFNs upon the 
stimulation of CDNs but not dsDNA. Given that CDNs can directly bind to 
STING, the results suggested that the STING pathway is not blocked by MRP 
in cancer cells. We also found that type I IFNs are able to be responsive to 
dsDNA in HeLa cells but not in 293T cells. This is possibly because the 
different ratio of MRP to STING in these cells, which means STING in 293T 
cells is completely blocked by MRP, while there are some functional STING 
in HeLa cells. It is also possible that there are different STING mutations in 
293T and HeLa cells. Further experiments are needed to characterize details of 
STING in these two cells lines, which can help us understand the interaction 
between MRP and STING. Because dsDNA fail to trigger the type I IFNs 
secretion, a possible reason for the dysfunction of type I IFN pathway is 
upstream of STING mediated pathway, such as cGAS deficiency on DNA 
recognition. Because CDNs can increase the level of cytosolic DNA presence, 
another possibility is the cytosolic DNA induced by CDNs is different from 
dsDNA that cannot trigger type I IFNs production. The result also suggested a 
new pathway for STING mediated pathway that CDNs could not only directly 
bind to STING, but also affect cGAS by induce cytosolic DNA accumulation. 
Further studies will be needed to be conducted to characterize cGAS and its 
recognition of dsDNA in different cancer cells.  
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6.3 Future work 
In light of the phenotype that we observed in STING-deficient cancer cells, 
more experiments are needed to understand the relationship between STING 
and cytosolic DNA accumulation in cancer cells. Our data suggest that, 
STING is an important adaptor molecule that links the pathway from cytosolic 
DNA sensors such as cGAS to downstream cytokines such as type I IFNs. It 
would be necessary to cross Sting-deficient mice with Eu-Myc mice, and 
further evaluate cytokines expression levels. 
An important question is the mechanism of MRP in cancer cells. It would be 
worthwhile to identify potential interacting partners of MRP. By comparing 
MRP with STING, this can provide insights into the mechanism of MRP and 
STING regulation over type I IFNs mediated signaling pathway as well as 
other immune innate activities such as NF-κB expression. In addition, because 
genome instability is one of the cancer hallmarks, it will be interesting to 
investigate the role of STING in the DDR (Hanahan and Weinberg, 2011). 
It would also be worthwhile to study if loss of MRP could lead to the normal 
function of type I IFN pathway in human cancer cell lines. With the highly 
efficient CRISPR system, it is possible to utilize the system to generate 
MRP-deficient cells to do further research. 
6.4 Conclusion 
Here we investigated the potential role of STING in cancer cells. Our findings 
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suggest that STING is important for presence and sensing of cytosolic DNA in 
cancer cells. We provide evidence that the STING pathway is defective in 
some cancer cells lines. Hence the restoration of STING activity in ca ncer 
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